Literature DB >> 28691411

Kupffer cells in immune activation and tolerance toward HBV/HCV infection.

Fangchao Yuan1, Wenfeng Zhang1, Di Mu2, Jianping Gong1.   

Abstract

Kupffer cells (KCs) are macrophages that are found in the sinusoids of the liver. KCs are a crucial part of the innate immune system, acting as scavengers and phagocytes. KCs and sinusoidal endothelial cells together form the first immune barrier of the portal system. Studies show that KCs can not only maintain homeostasis in the immune response, but also facilitate the pathogenesis of type B and type C hepatitis (HBV/HCV) through their antigen-presenting function and secretion of soluble mediators. KCs can express toll-like receptors (TLRs), Fas ligand (FasL) and programmed cell death ligand 1 (PD-L1), and secrete large amounts of inflammatory factors leading to immune tolerance toward HBV/HCV. On the one hand, KCs contribute to the clearance of HBV/HCV due to their nature as innate immune cells. At the same time, KCs induce immune tolerance toward HBV/HCV, which leads to chronicity of the infection. The dual role of KCs in the immune response toward HBV/HCV means it is a gigantic challenge for scientists to illuminate the detailed mechanisms involved, but it also offers important potential therapeutic targets.

Entities:  

Keywords:  HBV; HCV; Kupffer cell

Mesh:

Substances:

Year:  2017        PMID: 28691411     DOI: 10.17219/acem/62759

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  10 in total

1.  Hepatitis C Virus Entry into Macrophages/Monocytes Mainly Depends on the Phagocytosis of Macrophages.

Authors:  Yuan Liu; Wenbo Wang; Ziying Zou; Zonghai Hu; Quanshui Fan; Jie Xiong
Journal:  Dig Dis Sci       Date:  2018-12-10       Impact factor: 3.199

Review 2.  Reversing immune dysfunction and liver damage after direct-acting antiviral treatment for hepatitis C.

Authors:  Sabrina Mazouz; Maude Boisvert; Naglaa H Shoukry; Daniel Lamarre
Journal:  Can Liver J       Date:  2018-07-17

3.  Enrichment Methods for Murine Liver Non-Parenchymal Cells Differentially Affect Their Immunophenotype and Responsiveness towards Stimulation.

Authors:  Carolina Medina-Montano; Maximiliano Luis Cacicedo; Malin Svensson; Maria Jose Limeres; Yanira Zeyn; Jean Emiro Chaves-Giraldo; Nadine Röhrig; Stephan Grabbe; Stephan Gehring; Matthias Bros
Journal:  Int J Mol Sci       Date:  2022-06-11       Impact factor: 6.208

4.  HBV and HIV/HBV Infected Patients Have Distinct Immune Exhaustion and Apoptotic Serum Biomarker Profiles.

Authors:  Mohamed Tarek M Shata; Enass A Abdel-Hameed; Susan D Rouster; Li Yu; Meina Liang; Esther Song; Mark T Esser; Norah Shire; Kenneth E Sherman
Journal:  Pathog Immun       Date:  2019-02-13

5.  CD49a Expression Identifies a Subset of Intrahepatic Macrophages in Humans.

Authors:  Glòria Martrus; Hanna Goebels; Annika E Langeneckert; Janine Kah; Felix Flomm; Annerose E Ziegler; Annika Niehrs; Sebastian M Löbl; Kristina Russu; Leonard U Hess; Wilhelm Salzberger; Tobias Poch; Björn Nashan; Christoph Schramm; Karl J Oldhafer; Maura Dandri; Martina Koch; Sebastian Lunemann; Marcus Altfeld
Journal:  Front Immunol       Date:  2019-06-07       Impact factor: 7.561

6.  Modulation of calcium signaling pathway by hepatitis C virus core protein stimulates NLRP3 inflammasome activation.

Authors:  Amina A Negash; Rebecca M Olson; Stephen Griffin; Michael Gale
Journal:  PLoS Pathog       Date:  2019-02-27       Impact factor: 6.823

Review 7.  The Role of Immune Checkpoint Molecules on Macrophages in Cancer, Infection, and Autoimmune Pathologies.

Authors:  Victoria C Brom; Christof Burger; Dieter C Wirtz; Frank A Schildberg
Journal:  Front Immunol       Date:  2022-03-28       Impact factor: 7.561

Review 8.  Toll-like receptor-mediated innate immunity orchestrates adaptive immune responses in HBV infection.

Authors:  Yanqin Du; Jun Wu; Jia Liu; Xin Zheng; Dongliang Yang; Mengji Lu
Journal:  Front Immunol       Date:  2022-07-29       Impact factor: 8.786

Review 9.  Advances and challenges of immunocheckpoint inhibitors in the treatment of primary liver cancer.

Authors:  Meng Hu; Weirong Yao; Qinglin Shen
Journal:  Front Genet       Date:  2022-09-30       Impact factor: 4.772

Review 10.  Microbiota-Meditated Immunity Abnormalities Facilitate Hepatitis B Virus Co-Infection in People Living With HIV: A Review.

Authors:  Jing Ouyang; Silvere D Zaongo; Xue Zhang; Miaomiao Qi; Aizhen Hu; Hao Wu; Yaokai Chen
Journal:  Front Immunol       Date:  2022-01-06       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.